Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin (COMMIT)

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: insulin aspart; Drug: biphasic insulin aspart 30; Drug: insulin detemir

Study type: Observational

Funder types: Industry

Identifiers

NCT00676741

BIASP-3516

Details and patient eligibility

About

The study is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control in patients using a modern insulin: NovoRapid®, NovoMix® 30 or Levemir® for the treatment type 2 diabetes.

Full acronym for this study: COMMIT - CLEAN SWITCH

Enrollment: 3,809 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with type 2 diabetes
• Patients treated with human soluble insulin, NPH insulin or premixed human insulin
• Patients willing to sign informed consent
• Selection of study participants at the discretion of the physician

Exclusion criteria

• Subjects currently being treated with insulin aspart, insulin detemir or biphasic insulin aspart 30
• Subjects who were previously enrolled in this study
• Subjects with a hypersensitivity to insulin aspart, insulin detemir or biphasic insulin aspart 30 or to any of the excipients

Trial design

3,809 participants in 3 patient groups

A

Treatment:

Drug: insulin aspart

B

Treatment:

Drug: biphasic insulin aspart 30

C

Treatment:

Drug: insulin detemir